WILMINGTON, N.C.--(EON: Enhanced Online News)--Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Gregory Dennis, M.D., as vice president of global product development. In this role, Dr. Dennis serves as therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.
“Dr. Dennis brings extensive product development and commercialization experience and will play a key role in helping clients plan and address critical drug development challenges”
“Dr. Dennis brings extensive product development and commercialization experience and will play a key role in helping clients plan and address critical drug development challenges,” said Rob Dow, M.B.Ch.B., F.R.C.P. (Edin), F.F.P.M., global head of medical affairs for PPD. “His background with biopharmaceutical companies and government agencies adds value to PPD’s global clinical trial experience in a variety of rheumatology, immunology and inflammatory areas, including osteoarthritis, rheumatoid arthritis, gout, lupus and psoriasis.”
Deep therapeutic area expertise is integral to PPD’s comprehensive service offerings, including integrated laboratory, Phase I-IV and consulting services. PPD manages hundreds of clinical studies each year and leverages this expertise and experience to create optimal design decisions, efficient processes and economies of scale for clients.
Dr. Dennis comes to PPD from UCB, where he served as head of immunology for U.S. medical affairs and participated extensively in guiding compounds through the regulatory approval process. Previously, he held leadership roles at Human Genome Sciences, MedImmune and the National Institutes of Health. He retired from the U.S. Army Medical Corps as a colonel, chief of rheumatology and consultant to the army surgeon general.
Dr. Dennis earned a medical degree from St. Louis University and a bachelor’s degree in biology from the University of Missouri.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s new vice president, global product development, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate and retain key personnel; competition in the outsourcing industry; PPD’s ability to win new business; rapid technological advances that make our services less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.